Alembic Pharmaceuticals announced it received approval from the USFDA to market Nelarabine Injection, a generic cancer treatment drug. The estimated market size for Nelarabine Injection is USD 23 million for the twelve months ending March 2024. Alembic now has 211 ANDA approvals. Shares rose 1.93% to Rs 1,235 on NSE. This product, equivalent to Sandoz Inc’s Arranon Injection, treats T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
Alembic Pharma – Gets USFDA Approval for Generic Cancer Drug
